Based on the Alterity Therapeutics Ltd stock forecast from 1 analysts, the average analyst target price for Alterity Therapeutics Ltd is USD 10.00 over the next 12 months. Alterity Therapeutics Ltd’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Alterity Therapeutics Ltd is Bearish, which is based on 3 positive signals and 8 negative signals. At the last closing, Alterity Therapeutics Ltd’s stock price was USD 2.76. Alterity Therapeutics Ltd’s stock price has changed by -20.00% over the past week, -25.81% over the past month and +46.81% over the last year.
No recent analyst target price found for Alterity Therapeutics Ltd
No recent average analyst rating found for Alterity Therapeutics Ltd
Company Overview Alterity Therapeutics Ltd
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia. Read Less
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug cand...Read More
Frequently Asked Questions About Alterity Therapeutics Ltd (ATHE) Stock
Based on ratings from 1 analysts Alterity Therapeutics Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on ATHE's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for ATHE is USD 10.00 over the next 12 months. The maximum analyst target price is USD 12 while the minimum anlayst target price is USD 8.
ATHE stock's Price/Earning ratio is -99,999.99.
Our analysis grades ATHE stock's Price / Earning ratio at A. This means that ATHE stock's Price/Earning ratio is above 4.000000000000004% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ATHE may be undervalued for its sector.
The last closing price of ATHE's stock was USD 2.76.
The most recent market capitalization for ATHE is USD 0.04B.
Based on targets from 1 analysts, the average taret price for ATHE is projected at USD 10.00 over the next 12 months.
This means that ATHE's stock price may go up by +294.48% over the next 12 months.
We can't find any ETFs which contains Alterity Therapeutics Ltd's stock.
As per our most recent records Alterity Therapeutics Ltd has 10 Employees.
Alterity Therapeutics Ltd's registered address is 350 Collins Street, Melbourne, VIC, Australia, 3000.
You can get more information about it from Alterity Therapeutics Ltd's website at https://alteritytherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative earnings
The company had negative total earnings in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Alterity Therapeutics Ltd (ATHE) Stock
Based on ratings from 1 analysts Alterity Therapeutics Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on ATHE's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for ATHE is USD 10.00 over the next 12 months. The maximum analyst target price is USD 12 while the minimum anlayst target price is USD 8.
ATHE stock's Price/Earning ratio is -99,999.99.
Our analysis grades ATHE stock's Price / Earning ratio at A. This means that ATHE stock's Price/Earning ratio is above 4.000000000000004% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ATHE may be undervalued for its sector.
The last closing price of ATHE's stock was USD 2.76.
The most recent market capitalization for ATHE is USD 0.04B.
Based on targets from 1 analysts, the average taret price for ATHE is projected at USD 10.00 over the next 12 months.
This means that ATHE's stock price may go up by +294.48% over the next 12 months.
We can't find any ETFs which contains Alterity Therapeutics Ltd's stock.
As per our most recent records Alterity Therapeutics Ltd has 10 Employees.
Alterity Therapeutics Ltd's registered address is 350 Collins Street, Melbourne, VIC, Australia, 3000.
You can get more information about it from Alterity Therapeutics Ltd's website at https://alteritytherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ATHE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
